The science of vaccine safety: Summary of meeting at Wellcome Trust.
The objective of the meeting was to assess what is known beyond reasonable doubt and conversely what areas need additional studies. Although the meeting could not cover all aspects of vaccine safety science, many of the most important issues were addressed by a group of about 30 experts to determine what is already known and what additional studies are merited to assess the safety of the vaccines currently in use. The meeting began with reviews of the current situation in different parts of the world, followed by reviews of specific controversial areas, including the incidence of certain conditions after vaccination and the safety of certain vaccine components. Lastly, information about the human papillomavirus vaccine was considered because its safety has been particularly challenged by vaccine opponents. The following is a summary of the meeting findings. In addition to this summary, the meeting organizers will explore opportunities to perform studies that would enlarge knowledge of vaccine safety. PMID: 31987690 [PubMed - as supplied by publisher]
Condition: Dengue Fever Interventions: Biological: 9vHPV vaccine; Biological: Dengue Tetravalent Vaccine (TDV) Sponsor: Takeda Not yet recruiting
Conditions: HIV Infections; HPV Infection Intervention: Biological: Human Papillomavirus 9-valent Vaccine, Recombinant Sponsors: University Hospital Virgen de las Nieves; Instituto de Salud Carlos III Recruiting